Melanotan II

Understand

Overview

Melanotan II (MT-II, MT2) is a synthetic, non-selective melanocortin receptor agonist, originally developed in the 1980s at the University of Arizona as a potential anti-skin-cancer agent through induced skin darkening (tanning) without UV exposure. The original research goal — skin cancer protection in very fair-skinned people via increased natural melanin-based photoprotection — never led to drug registration for MT-II itself. Instead, in the latter half of the 2000s the substance appeared on the online market as an illegal, unapproved "self-tanning" agent, sold via subcutaneous injection with no medical oversight whatsoever.

This is a fundamentally different situation from the related molecule afamelanotide (Melanotan I, trade name Scenesse), which went through full drug registration and is an FDA- and EMA-approved treatment for erythropoietic protoporphyria, a rare genetic disease causing extreme skin light sensitivity. Afamelanotide is a selective MC1R agonist, delivered via an implanted device under strict dermatological supervision for a specific medical indication. Melanotan II has none of this: it's a non-selective agonist acting simultaneously on MC1, MC3, MC4, and MC5 receptors, which explains the broad, often unpredictable range of its side effects extending far beyond simple skin darkening — including effects on appetite, libido, and sexual function mediated by the MC4R receptor in the central nervous system.

This non-selectivity is the key to understanding why Melanotan II deserves particular caution compared with other peptides covered in this category. While BPC-157 or TB-500 mainly have a problem of lacking effectiveness evidence, Melanotan II has the opposite, more serious problem: solid, repeatedly confirmed documentation across independent publications of real, sometimes severe adverse effects, including acute complications requiring surgical intervention (priapism) and, particularly concerning given its mechanism of action, documented melanoma cases in users.

The first Phase I pilot study in humans, conducted in 1996 on three healthy men receiving escalating subcutaneous doses of MT-II, confirmed dose-dependent skin darkening, but even in this tiny study researchers noted nausea, facial flushing, and — notably, since this was not expected while developing the drug as an anti-cancer agent — spontaneous penile erections as a side effect. It was precisely this unexpected observation from the first human study that steered some subsequent melanocortin-derivative research toward erectile and sexual dysfunction (from which the approved drug bremelanotide, Vyleesi, used for sexual desire disorders in women, is derived) — but Melanotan II itself never completed clinical development and never obtained registration for any indication.

Regulatory agencies in multiple countries have issued formal consumer warnings about Melanotan II. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) received dozens of reports covering dozens of different adverse reactions related to its use, including gastrointestinal, cardiac, blood, and eye problems, while Cancer Research UK and the American Skin Cancer Foundation issued public warnings specifically addressing the oncological risk tied to this substance's mechanism of action. Independent laboratory analyses of vials seized in the UK and Australia have repeatedly found wide variation in actual peptide content relative to the label, frequent bacterial contamination, elevated endotoxin levels, and unidentified peptide impurities — meaning that even the theoretical risk of the pure molecule itself is, in practice, further compounded by a total lack of quality control over the product reaching the consumer.

The group most at risk of encountering Melanotan II are very fair-skinned people seeking an alternative to sun or tanning-bed exposure, parts of the bodybuilding community exploiting its appetite and libido effects as a "bonus," and young people buying the product online without fully grasping that something labeled a "tanning peptide" is not a cosmetic or supplement but an unapproved, injectable compound pharmacologically active throughout the entire body, not just the skin.

History of use

Melanotan II was synthesized in the 1980s in Victor Hruby's lab at the University of Arizona, as part of research into alpha-MSH analogs as potential photoprotective and anti-cancer agents. The first Phase I pilot study in humans (Dorr et al., 1996) confirmed skin-darkening activity but revealed an unexpected side effect — spontaneous erections — which steered subsequent commercial research toward sexual dysfunction rather than tanning. Development rights in that direction were taken up by Palatin Technologies, which eventually led to registration of a different melanocortin analog, bremelanotide (Vyleesi), approved by the FDA in 2019 for sexual desire disorders in women — but not Melanotan II itself. From the mid-2000s, MT-II began circulating in online sales as an illegal "tanning peptide," and from 2007–2009 British and Australian public health agencies began issuing the first formal consumer warnings in response to a growing number of adverse-effect reports.